Malvinder & Shivinder Singh
Health care

Malvinder & Shivinder Singh Net Worth

11 months from now

Malvinder and Shivinder Singh, two brothers from Delhi, India, have recently faced a major setback when a Singapore arbitration court imposed a $390 million fine on them for allegedly misrepresenting facts when they sold their pharma firm, Ranbaxy Laboratories, to Japan's Daiichi Sankyo 8 years ago. The Singhs deny any wrongdoing and are contesting the ruling in both Singapore and India. In response, Malvinder is demerging the hospital chain, Fortis Healthcare, which he runs as executive chairman, and the brothers have rejoined the board of financial firm Religare Enterprises in a non-executive capacity. Shivinder has also retired from business to work for a spiritual organization.
Malvinder & Shivinder Singh is a member of Health care

Age, Biography and Wiki

Birth Place Delhi, India, India

💰 Net worth: $1.38 Billion (2024)

Malvinder and Shivinder Singh are prominent figures in the healthcare industry in India. As successful businessmen and entrepreneurs, their net worth is estimated to be an impressive $1.38 billion by the year 2024. Known for their investments and ventures in the healthcare sector, the Singh brothers have played a significant role in transforming the landscape of healthcare services in India. Their entrepreneurial journey has seen the establishment of several healthcare companies, bringing cutting-edge technology and innovative solutions to the Indian healthcare system. With their substantial net worth, the Singh brothers continue to make valuable contributions to the growth and development of healthcare in India.

2009 $2.6 Billion
2010 $3.2 Billion
2011 $4.1 Billion
2012 $3.5 Billion
2013 $2.6 Billion
2014 $2.1 Billion
2015 $2.3 Billion
2018 $1.1 Billion

Biography/Timeline

1999

Malvinder Mohan Singh is one of the son of Dr. Parvinder Singh and the grandson of Bhai Mohan Singh, the founder of Ranbaxy. He and his brother Shivinder Singh, who in 1999 upon the death of their Father inherited their family's 33.5% stake in Ranbaxy, are among the twenty richest Indians.

2008

Malvinder Singh's tenure as CEO of Ranbaxy starting in 2006 is controversial. Corporate culture of fraud continued unchecked under his tenure. In November 2006, Malvinder Singh led a delegation to FDA headquarters to try to reverse the decision to accept new drug applications from Ranbaxy. This attempt failed as FDA asked Ranbaxy to turn over audits done by its outside consultant, Parexel, which the company was claiming were confidential. The meeting ended in a standoff. Soon thereafter Mr. Singh decided to cash in. On 11 June 2008, Singh stunned the Indian Business world by announcing that he and his brother were selling their 34% stake in Ranbaxy to the Japanese drugmaker Daiichi Sankyo for $2 billion.

Some Malvinder & Shivinder Singh images

Tags The Doon School alumni Indian businesspeople in the pharmaceutical industry Fuqua School of Business alumni Indian Sikhs Living people Indian business biography stubs

You may also like

About the author

Lisa Scholfield

As a Senior Writer at Famous Net Worth, I spearhead an exceptional team dedicated to uncovering and sharing the stories of pioneering individuals. My passion for unearthing untold narratives drives me to delve deep into the essence of each subject, bringing forth a unique blend of factual accuracy and narrative allure. In orchestrating the editorial workflow, I am deeply involved in every step—from initial research to the final touches of publishing, ensuring each biography not only informs but also engages and inspires our readership.